---
title: 'Clinical Daily Summary: What Happened on October 25, 2026'
headline: ESMO features two Cyclin E1 candidates for ovarian cancer
description: ''
url: https://thebench.bio/news/clinical/2026-10-25
topic: clinical
date: '2026-10-25'
covers:
- '2026-10-25'
date_published: '2026-10-25T12:00:33Z'
date_modified: '2026-10-25T12:00:33Z'
tags:
- Industry
sources: 2
publisher: TheBench.Bio
---

# Clinical Daily Summary: What Happened on October 25, 2026

**ESMO features two Cyclin E1 candidates for ovarian cancer**

## Today in brief

ESMO26 included data on two candidates targeting Cyclin E1 in platinum-resistant ovarian cancer. [1] The VOLGA headline focused on perioperative bladder cancer therapy at the conference. [2]

## Sources

1. [ESMO26: Oral cell cycle inhibitors place Cyclin E1 as new target in PROC](<https://www.pharmaceutical-technology.com/analyst-comment/esmo26-oral-cell-cycle-inhibitors-place-cyclin-e1-as-new-target-in-proc/>), Pharmaceutical Technology, 2026-10-25
2. [ESMO26: VOLGA stirs up perioperative bladder cancer therapy](<https://pharmaphorum.com/news/esmo26-volga-stirs-perioperative-bladder-cancer-therapy>), pharmaphorum, 2026-10-25

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/analyst-comment/esmo26-oral-cell-cycle-inhibitors-place-cyclin-e1-as-new-target-in-proc/>
[2]: <https://pharmaphorum.com/news/esmo26-volga-stirs-perioperative-bladder-cancer-therapy>